Switch to:
Also traded in: Germany, Israel, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.46
OPK's Cash to Debt is ranked lower than
74% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. OPK: 1.46 )
Ranked among companies with meaningful Cash to Debt only.
OPK' s Cash to Debt Range Over the Past 10 Years
Min: 0.13  Med: 34.00 Max: No Debt
Current: 1.46
Equity to Asset 0.65
OPK's Equity to Asset is ranked lower than
53% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. OPK: 0.65 )
Ranked among companies with meaningful Equity to Asset only.
OPK' s Equity to Asset Range Over the Past 10 Years
Min: -0.41  Med: 0.66 Max: 0.96
Current: 0.65
-0.41
0.96
F-Score: 6
Z-Score: 2.16
M-Score: 0.98
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) -51.02
OPK's Operating margin (%) is ranked higher than
53% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. OPK: -51.02 )
Ranked among companies with meaningful Operating margin (%) only.
OPK' s Operating margin (%) Range Over the Past 10 Years
Min: -31624.44  Med: -121.45 Max: -39.08
Current: -51.02
-31624.44
-39.08
Net-margin (%) -35.09
OPK's Net-margin (%) is ranked higher than
56% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. OPK: -35.09 )
Ranked among companies with meaningful Net-margin (%) only.
OPK' s Net-margin (%) Range Over the Past 10 Years
Min: -31688.9  Med: -153.46 Max: -4.59
Current: -35.09
-31688.9
-4.59
ROE (%) -7.89
OPK's ROE (%) is ranked higher than
69% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. OPK: -7.89 )
Ranked among companies with meaningful ROE (%) only.
OPK' s ROE (%) Range Over the Past 10 Years
Min: -3196.93  Med: -21.01 Max: -3.98
Current: -7.89
-3196.93
-3.98
ROA (%) -4.91
OPK's ROA (%) is ranked higher than
71% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. OPK: -4.91 )
Ranked among companies with meaningful ROA (%) only.
OPK' s ROA (%) Range Over the Past 10 Years
Min: -1352.71  Med: -13.92 Max: -0.83
Current: -4.91
-1352.71
-0.83
ROC (Joel Greenblatt) (%) -338.34
OPK's ROC (Joel Greenblatt) (%) is ranked higher than
51% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. OPK: -338.34 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OPK' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -130662.93  Med: -408.75 Max: -55.31
Current: -338.34
-130662.93
-55.31
Revenue Growth (3Y)(%) 30.10
OPK's Revenue Growth (3Y)(%) is ranked higher than
84% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. OPK: 30.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
OPK' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -22.55 Max: 135.1
Current: 30.1
0
135.1
EBITDA Growth (3Y)(%) 69.40
OPK's EBITDA Growth (3Y)(%) is ranked higher than
96% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. OPK: 69.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OPK' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -75.7  Med: 1.55 Max: 171.4
Current: 69.4
-75.7
171.4
EPS Growth (3Y)(%) 133.40
OPK's EPS Growth (3Y)(%) is ranked higher than
99% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. OPK: 133.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OPK' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -69.4  Med: 3.40 Max: 149.7
Current: 133.4
-69.4
149.7
» OPK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

OPK Guru Trades in Q1 2015

Paul Tudor Jones 38,137 sh (New)
Jim Simons 1,253,398 sh (New)
Ken Fisher 29,200 sh (New)
George Soros 235,600 sh (unchged)
Mario Gabelli 11,000 sh (unchged)
Murray Stahl 94,824 sh (-24.59%)
» More
Q2 2015

OPK Guru Trades in Q2 2015

Joel Greenblatt 42,947 sh (New)
Paul Tudor Jones 119,791 sh (+214.11%)
Jim Simons 1,907,498 sh (+52.19%)
Murray Stahl 96,810 sh (+2.09%)
George Soros 235,600 sh (unchged)
Ken Fisher 29,200 sh (unchged)
Mario Gabelli 10,000 sh (-9.09%)
» More
Q3 2015

OPK Guru Trades in Q3 2015

John Hussman 750,000 sh (New)
Chuck Royce 521,525 sh (New)
Mario Gabelli 169,900 sh (+1599.00%)
Ken Fisher 35,500 sh (+21.58%)
George Soros Sold Out
Joel Greenblatt Sold Out
Jim Simons Sold Out
Murray Stahl 94,118 sh (-2.78%)
Paul Tudor Jones 46,800 sh (-60.93%)
» More
Q4 2015

OPK Guru Trades in Q4 2015

Ken Fisher 37,826 sh (+6.55%)
John Hussman Sold Out
Mario Gabelli 144,775 sh (-14.79%)
» More
» Details

Insider Trades

Latest Guru Trades with OPK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Opko Health Inc

Weekly CEO Buys Highlights Citigroup, Opko, JMP Group, Tuesday Morning, Calamos lead list, according to GuruFocus Insider Data
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: FS Investment, Opko, Ambac, Calamos, Praxair These are the largest CEO buys during the past week, according to GuruFocus' Insider Data
These are the largest CEO buys during the past week, according to GuruFocus' Insider Data. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: GHL, OPK, DKL, ATI, PEB A look at recent insider buys from CEOs
According to GuruFocus Insider Data, these were the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: Box, Opko, Neonode, FS Investment, Celator Pharmaceuticals GuruFocus Insider Data identifies CEOs' largest buys in the past week.
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: CC, OPK, PX, PSG, JOY A roundup of recent insider buys
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEO buys is illustrated in the chart below: Read more...
Weekly CEO Buys Highlight: Tesla, Opko, MasTec, NSA Trust, Conifer Holdings
According to GuruFocus Insider Data, these are the largest CEO buys during the past week. The overall trend of CEOs is illustrated in the chart below: Read more...

Ratios

vs
industry
vs
history
Forward P/E 16.69
OPK's Forward P/E is ranked higher than
51% of the 344 Companies
in the Global Biotechnology industry.

( Industry Median: 16.75 vs. OPK: 16.69 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 2.13
OPK's P/B is ranked higher than
59% of the 1123 Companies
in the Global Biotechnology industry.

( Industry Median: 2.60 vs. OPK: 2.13 )
Ranked among companies with meaningful P/B only.
OPK' s P/B Range Over the Past 10 Years
Min: 2.12  Med: 8.87 Max: 50.6
Current: 2.13
2.12
50.6
P/S 14.82
OPK's P/S is ranked lower than
63% of the 1126 Companies
in the Global Biotechnology industry.

( Industry Median: 8.95 vs. OPK: 14.82 )
Ranked among companies with meaningful P/S only.
OPK' s P/S Range Over the Past 10 Years
Min: 14.83  Med: 34.80 Max: 126.5
Current: 14.82
14.83
126.5
PFCF 25.05
OPK's PFCF is ranked higher than
53% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 29.57 vs. OPK: 25.05 )
Ranked among companies with meaningful PFCF only.
OPK' s PFCF Range Over the Past 10 Years
Min: 24.85  Med: 36.39 Max: 49.65
Current: 25.05
24.85
49.65
POCF 22.80
OPK's POCF is ranked higher than
54% of the 384 Companies
in the Global Biotechnology industry.

( Industry Median: 25.81 vs. OPK: 22.80 )
Ranked among companies with meaningful POCF only.
OPK' s POCF Range Over the Past 10 Years
Min: 22.63  Med: 34.29 Max: 48.23
Current: 22.8
22.63
48.23
Current Ratio 1.45
OPK's Current Ratio is ranked lower than
82% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. OPK: 1.45 )
Ranked among companies with meaningful Current Ratio only.
OPK' s Current Ratio Range Over the Past 10 Years
Min: 0.88  Med: 5.93 Max: 415
Current: 1.45
0.88
415
Quick Ratio 1.33
OPK's Quick Ratio is ranked lower than
80% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. OPK: 1.33 )
Ranked among companies with meaningful Quick Ratio only.
OPK' s Quick Ratio Range Over the Past 10 Years
Min: 0.48  Med: 5.29 Max: 415
Current: 1.33
0.48
415
Days Inventory 79.17
OPK's Days Inventory is ranked higher than
68% of the 416 Companies
in the Global Biotechnology industry.

( Industry Median: 126.53 vs. OPK: 79.17 )
Ranked among companies with meaningful Days Inventory only.
OPK' s Days Inventory Range Over the Past 10 Years
Min: 131.84  Med: 255.62 Max: 500.07
Current: 79.17
131.84
500.07
Days Sales Outstanding 287.25
OPK's Days Sales Outstanding is ranked lower than
93% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. OPK: 287.25 )
Ranked among companies with meaningful Days Sales Outstanding only.
OPK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.86  Med: 163.92 Max: 727.85
Current: 287.25
38.86
727.85
Days Payable 273.60
OPK's Days Payable is ranked higher than
87% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 57.67 vs. OPK: 273.60 )
Ranked among companies with meaningful Days Payable only.
OPK' s Days Payable Range Over the Past 10 Years
Min: 66.48  Med: 118.54 Max: 1499.3
Current: 273.6
66.48
1499.3

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.80
OPK's Price/Projected FCF is ranked higher than
57% of the 298 Companies
in the Global Biotechnology industry.

( Industry Median: 3.18 vs. OPK: 2.80 )
Ranked among companies with meaningful Price/Projected FCF only.
OPK' s Price/Projected FCF Range Over the Past 10 Years
Min: 3.04  Med: 14.63 Max: 236.67
Current: 2.8
3.04
236.67
Price/Median PS Value 0.45
OPK's Price/Median PS Value is ranked higher than
81% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. OPK: 0.45 )
Ranked among companies with meaningful Price/Median PS Value only.
OPK' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.32  Med: 1.31 Max: 9.86
Current: 0.45
0.32
9.86
Price/Graham Number 5.04
OPK's Price/Graham Number is ranked lower than
75% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 2.40 vs. OPK: 5.04 )
Ranked among companies with meaningful Price/Graham Number only.
OPK' s Price/Graham Number Range Over the Past 10 Years
Min: 1.26  Med: 4.70 Max: 17.57
Current: 5.04
1.26
17.57
Earnings Yield (Greenblatt) (%) -3.87
OPK's Earnings Yield (Greenblatt) (%) is ranked higher than
59% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. OPK: -3.87 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OPK' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -7.03  Med: 0.00 Max: 0
Current: -3.87
-7.03
0

More Statistics

Revenue(Mil) $241
EPS $ -0.22
Beta1.82
Short Percentage of Float30.29%
52-Week Range $7.12 - 19.20
Shares Outstanding(Mil)545.01

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 469 1,090 1,512 2,153
EPS($) -0.13 0.04 0.47 0.97
EPS without NRI($) -0.13 0.04 0.47 0.97

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:XCY.Germany, OPK.Israel, OPK.Mexico,
Opko Health Inc was originally incorporated in Delaware in October 1991 under the name Cytoclonal Pharmaceutics, Inc. The Company is a multi-national biopharmaceutical and diagnostics company. It is developing various solutions to diagnose, treat and prevent various conditions, including point-of-care tests, laboratory developed tests, molecular diagnostics tests, and proprietary pharmaceuticals and vaccines. It owns established pharmaceutical platforms in Chile, Spain, Mexico and Uruguay. It also has established pharmaceutical operations in Brazil. The Company owns a specialty active pharmaceutical ingredients manufacturer in Israel. The Company currently manages its operations in two reportable segments, pharmaceutical and diagnostics. The pharmaceutical segment consists of two operating segments, its (i) pharmaceutical research and development segment which is focused on the research and development of pharmaceutical products and vaccines, and (ii) the pharmaceutical operations it acquired in Chile, Spain, Mexico, Israel, Spain, Uruguay and Brazil. The diagnostics segment consists of two operating segments, the Companys (i) pathology operations it acquired through the acquisition of OPKO Lab and (ii) point-of-care and molecular diagnostics operations. Its main products Rayaldy and Alpharen are in phase 3 clinical development. Its competitors include diagnostic companies, reference laboratories, molecular diagnostic firms, universities and research institutions. The testing, manufacture, distribution, advertising, and marketing of drug and diagnostic products and medical devices are subject to extensive regulation by federal, state, and local governmental authorities in the U.S., including the FDA, and by similar agencies in other countries.
» More Articles for OPK

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlights Jan 26 2016 
Weekly CEO Buys Highlight: FS Investment, Opko, Ambac, Calamos, Praxair Jan 11 2016 
Weekly CEO Buys Highlights for the Final Week of 2015 Jan 04 2016 
Weekly CEO Buys Highlight: Prospect Capital, Sears Holdings, Calamos Asset Management, Opko Health, Dec 28 2015 
Weekly CEO Buys Highlight: GHL, OPK, DKL, ATI, PEB Nov 02 2015 
Weekly CEO Buys Highlight: Box, Opko, Neonode, FS Investment, Celator Pharmaceuticals Oct 16 2015 
Weekly CEO Buys Highlight: CC, OPK, PX, PSG, JOY Sep 12 2015 
Weekly CEO Buys Highlight: Shutterstock, Endurance Specialty Holdings, Opko, Air Products, KapStone Aug 31 2015 
Top Insider Buys of the Week Aug 28 2015 
Weekly CEO Buys Highlight: Tesla, Opko, MasTec, NSA Trust, Conifer Holdings Aug 24 2015 

More From Other Websites
8:43 am Opko Health reports study results that shows its 4Kscore Test's led to a 64.6% reduction in... Feb 09 2016
Study Demonstrates OPKO’s 4Kscore Test Reduces Unnecessary Prostate Biopsies While Improving Risk... Feb 09 2016
Fitbit, Tesla Lead List Of Hot Stocks In Short-Selling Circles Feb 05 2016
A Company's First Profit Can Mean Big Profits to Investors Jan 26 2016
Weekly CEO Buys Highlights Jan 26 2016
Technical Recap on Biotechnology Stocks -- Nektar Therapeutics, Novavax, Celgene, and Opko Health Jan 25 2016
OPKO’s GeneDx to Present at Personalized Medicine World Conference Jan 22 2016
Weekly CEO Buys Highlight: FS Investment, Opko, Ambac, Calamos, Praxair Jan 11 2016
OPKO Health to Present at the J.P. Morgan 34th Annual Healthcare Conference Jan 06 2016
OPKO Health to Present at the J.P. Morgan 34th Annual Healthcare Conference Jan 06 2016
OPKO HEALTH, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 05 2016
Conversion Right Extended on OPKO 3.0% Convertible Senior Notes Jan 05 2016
Conversion Right Extended on OPKO 3.0% Convertible Senior Notes Jan 05 2016
Weekly CEO Buys Highlights for the Final Week of 2015 Jan 04 2016
OPKO Health, Inc. breached its 50 day moving average in a Bullish Manner : December 30, 2015 Dec 30 2015
Weekly CEO Buys Highlight: Prospect Capital, Sears Holdings, Calamos Asset Management, Opko ... Dec 28 2015
OPKO’s GeneDx Study of More Than 10,000 Individuals Tested with Multigene NGS Hereditary Cancer... Dec 21 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK